Godavari Drugs Ltd

Godavari Drugs Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, despite ongoing challenges in the Pharmaceuticals & Biotechnology sector. This revaluation comes amid a backdrop of mixed returns relative to the Sensex and a micro-cap market capitalisation, prompting investors to reassess the stock’s price attractiveness in comparison to its peers.

Godavari Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 09 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 12 August 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Godavari Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Godavari Drugs Ltd is rated Sell by MarketsMOJO. This rating was last updated on 09 July 2026, reflecting a change from the previous Hold rating. However, the analysis and financial metrics discussed below represent the stock’s current position as of 21 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Godavari Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 9 July 2026. This decision follows a comprehensive reassessment across four critical parameters: quality, valuation, financial trend, and technicals. Despite delivering market-beating returns over the past year, the company’s deteriorating fundamentals and mixed technical signals have prompted a cautious stance from analysts.

Godavari Drugs Ltd has seen its investment rating upgraded from Sell to Hold as of 3 July 2026, reflecting a notable improvement in its technical indicators and valuation metrics despite flat recent financial performance. The pharmaceutical company’s stock has outperformed the broader market over the past year, prompting a reassessment of its prospects across quality, valuation, financial trend, and technical parameters.

Godavari Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 22 June 2026. This change reflects a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments that collectively signal caution for investors despite some market-beating returns over the past year.

Godavari Drugs Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and valuation metrics despite ongoing challenges in financial performance. The upgrade, effective from 16 June 2026, is driven primarily by enhanced technical trends, attractive valuation ratios, and increased institutional participation, positioning the micro-cap pharmaceutical firm for cautious optimism amid a mixed fundamental backdrop.

Godavari Drugs Ltd has seen its investment rating downgraded from Hold to Sell as of 11 June 2026, reflecting a complex interplay of technical, valuation, financial trend, and quality factors. Despite a strong year-to-date return of 50.98%, the company’s deteriorating fundamentals and mixed technical signals have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Godavari Drugs Ltd., a micro-cap active pharmaceutical ingredients (API) manufacturer, reported a robust performance in Q4 FY26 with net profit surging 69.66% quarter-on-quarter to ₹1.29 crores, whilst revenue jumped an impressive 49.50% to ₹33.16 crores. However, the positive quarterly momentum stands in stark contrast to the company's troubling five-year track record of negative sales growth and deteriorating operational efficiency, raising critical questions about the sustainability of this recent upturn.

Surging past Rs 135.25 on 27 May 2026, Godavari Drugs Ltd has reached a fresh 52-week high, marking a 31.51% gain over the past year against the Sensex’s decline of 6.83%. This milestone caps a four-day winning streak that has propelled the stock 6.24% higher, underscoring a robust price momentum that stands out in the Pharmaceuticals & Biotechnology sector.

Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Surging to a fresh 52-week high of Rs 134.5 on 11 May 2026, Godavari Drugs Ltd has demonstrated remarkable price momentum, outperforming the broader market with a 39.21% gain over the past year compared to the Sensex’s decline of 3.94%. This milestone underscores a sustained rally driven predominantly by strong technical signals across multiple timeframes.

Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Surging past its previous peaks, Godavari Drugs Ltd touched a fresh 52-week high of Rs 132.96 on 29 Apr 2026, marking a significant milestone in its price momentum. This rally has been underpinned by a confluence of bullish technical indicators and sustained outperformance relative to its sector and the broader market.